InFlectis BioScience
PrivateLast Round
Grant
Apr 30, 2024
Total Funding Raised
$9.5M
Company Overview
InFlectis BioScience is a biotechnology company that develops small molecule drugs to treat neuromuscular and neurodegenerative diseases by modulating the Integrated Stress Response.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
InFlectis BioScience Comparables
Compare InFlectis BioScience with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Augustine Therapeutics | 78% | |
| Alphabet Inc. | 75% | |
| Novartis | 74% |
InFlectis BioScience Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Apr 30, 2024 | ||||
| Grant | Jan 3, 2024 | ||||
| Strategic | Jun 22, 2021 | ||||
| Series A | Jun 1, 2016 | ||||
| Seed | Dec 3, 2014 |
Key People
Founding team and executive leadership
InFlectis BioScience Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The ALS Association | Grant |
| Remiges Ventures | Series A |
| GO Capital | Series A, Seed |
| Crédit Mutuel Innovation | Series A |
InFlectis BioScience Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access